Presenters
Cardiologist, FACC, FAHA
Sanjay Kaul, FACC, FAHA
Course Details
The lecture is about discussion on the results of the EMPagliflozin outcomE tRial in patients With chrOnic heaRt failure with Reduced ejection fraction and Preserved ejection fraction
CPD Points: 0.75 Point
PRC Program No: PROG-2021-20618
Towards the Cardio-Renal management of Heart Failure patients Course Outline
- To provide updates on the new indication of Empagliflozin in the treatment of patients with Heart failure reduced ejection fraction with or without T2D.
- Discussion on the Unmet Needs in Heart Failure Treatment touching on the current available therapies in HF.
- To discuss on early evidence of heart failure benefit in SGLT-2i.
- To discuss on the trial results of EMPagliflozin outcomE tRial in patients With chrOnic heaRt failure with Preserved ejection fraction (EMPEROR-Preserved).
- To discuss on the trial results of EMPagliflozin outcomE tRial in patients With chrOnic heaRt failure with Reduced ejection fraction (EMPEROR-Reduced).